North America Skin Cancer Diagnostics Market Forecast 2023-2032

The North America skin cancer diagnostics market is expected to grow with a 7.28% CAGR during the estimation period 2023-2032. The market growth is driven by heavy R&D investments and a rapid increase in melanoma cases in the region.

MARKET INSIGHTS

The North America skin cancer diagnostics market growth evaluation covers a thorough assessment of Canada and the United States. Canada holds a prominent position globally in terms of national health expenditure. The Canadian Institute for Health Information has projected that the nation's total health spending is expected to touch $331 billion in 2022, which amounts to $8,563 per capita.

The Canadian government, recognizing the severity of this health crisis, has committed to intensifying efforts to tackle skin cancer. The Public Health Agency of Canada (PHAC), responsible for monitoring cancer trends in the country, plays a pivotal role in identifying risk factors, strategizing programs for risk reduction, and researching environmental and behavioral hazards. Furthermore, Health Canada spearheads initiatives to raise public awareness about sun safety and the detrimental effects of UV radiation.

The continued escalation in skin cancer prevalence, coupled with an unwavering commitment from governmental and private entities to elevate public consciousness about early cancer detection and preventive measures, is anticipated to serve as critical catalysts propelling the market growth.

COMPETITIVE INSIGHTS

Some of the leading market players include: Dermlite LLC, Castle Biosciences Inc, etc.

Our report offerings include:

Explore key findings of the overall market
Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
Market Segmentation caters to a thorough assessment of key segments with their market estimations
Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Product Code: 51877

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.5. MAJOR MARKET FINDINGS
- 2.5.1. INCREASING APPLICATION OF AI AND MACHINE LEARNING IN SKIN CANCER DIAGNOSIS TOOLS

3. MARKET DYNAMICS

3.1. KEY DRIVERS
- 3.1.1. INCREASING PREVALENCE OF SKIN CANCER
- 3.1.2. GROWING AWARENESS ABOUT SKIN CANCER DIAGNOSIS & TREATMENT
- 3.1.3. TECHNOLOGICAL ADVANCEMENTS IN SKIN CANCER DIAGNOSTIC PRODUCTS
3.2. KEY RESTRAINTS
- 3.2.1. HIGH COSTS ASSOCIATED WITH SKIN CANCER TREATMENTS
- 3.2.2. STRINGENT REGULATORY FRAMEWORK
- 3.2.3. LACK OF SKILLED MEDICAL PROFESSIONALS

4. KEY ANALYTICS

4.1. PARENT MARKET ANALYSIS
4.2. KEY MARKET TRENDS
4.3. PORTER'S FIVE FORCES ANALYSIS
- 4.3.1. BUYERS POWER
- 4.3.2. SUPPLIERS POWER
- 4.3.3. SUBSTITUTION
- 4.3.4. NEW ENTRANTS
- 4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
4.5. MARKET CONCENTRATION ANALYSIS
4.6. VALUE CHAIN ANALYSIS
- 4.6.1. RESEARCH AND DEVELOPMENT
- 4.6.2. MANUFACTURING
- 4.6.3. MARKETING AND SALES
- 4.6.4. DISTRIBUTION AND LOGISTICS
- 4.6.5. TRAINING AND SUPPORT

5. MARKET BY TYPE

5.1. MELANOMA
5.2. NON-MELANOMA

6. MARKET BY GENDER

6.1. MALE
6.2. FEMALE

7. MARKET BY SCREENING TYPE

7.1. SKIN BIOPSY
7.2. DERMATOSCOPY
7.3. LYMPH NODE
7.4. BIOPSY IMAGING TESTS
7.5. BLOOD TESTS

8. GEOGRAPHICAL ANALYSIS

8.1. NORTH AMERICA
- 8.1.1. MARKET SIZE & ESTIMATES
- 8.1.2. NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET DRIVERS
- 8.1.3. NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET CHALLENGES
- 8.1.4. KEY PLAYERS IN NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET
- 8.1.5. COUNTRY ANALYSIS
  - 8.1.5.1. UNITED STATES
  - 8.1.5.1.1. UNITED STATES SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
  - 8.1.5.2. CANADA
  - 8.1.5.2.1. CANADA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES

9. COMPETITIVE LANDSCAPE

9.1. KEY STRATEGIC DEVELOPMENTS
- 9.1.1. PRODUCT LAUNCHES & DEVELOPMENTS
- 9.1.2. PARTNERSHIPS & AGREEMENTS
9.2. COMPANY PROFILES
- 9.2.1. AMLO BIOSCIENCES LIMITED
- 9.2.2. BIOMERIEUX SA
- 9.2.3. CASTLE BIOSCIENCES INC
- 9.2.4. DERMLITE LLC
- 9.2.5. DERMTECH INC
- 9.2.6. F. HOFFMANN-LA ROCHE LTD
- 9.2.7. MICHELSON DIAGNOSTICS LTD
- 9.2.8. NERACARE GMBH
- 9.2.9. SKYLINEDX BV
- 9.2.10. VERISKIN INC

Product Code: 51877

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT - SKIN CANCER DIAGNOSTICS
TABLE 2: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, BY TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 3: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, BY TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 4: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, BY GENDER, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 5: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, BY GENDER, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 6: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, BY SCREENING TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 7: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, BY SCREENING TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 8: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 9: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 10: KEY PLAYERS OPERATING IN NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET
TABLE 11: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 12: LIST OF PARTNERSHIPS & AGREEMENTS

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
FIGURE 3: GROWTH PROSPECT MAPPING FOR NORTH AMERICA
FIGURE 4: MARKET CONCENTRATION ANALYSIS
FIGURE 5: VALUE CHAIN ANALYSIS
FIGURE 6: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY TYPE, IN 2022
FIGURE 7: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, BY MELANOMA, 2023-2032 (IN $ MILLION)
FIGURE 8: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, BY NON-MELANOMA, 2023-2032 (IN $ MILLION)
FIGURE 9: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY GENDER, IN 2022
FIGURE 10: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, BY MALE, 2023-2032 (IN $ MILLION)
FIGURE 11: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, BY FEMALE, 2023-2032 (IN $ MILLION)
FIGURE 12: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY SCREENING TYPE, IN 2022
FIGURE 13: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, BY SKIN BIOPSY, 2023-2032 (IN $ MILLION)
FIGURE 14: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, BY DERMATOSCOPY, 2023-2032 (IN $ MILLION)
FIGURE 15: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, BY LYMPH NODE, 2023-2032 (IN $ MILLION)
FIGURE 16: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, BY BIOPSY IMAGING TESTS, 2023-2032 (IN $ MILLION)
FIGURE 17: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, BY BLOOD TESTS, 2023-2032 (IN $ MILLION)
FIGURE 18: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)
FIGURE 19: UNITED STATES SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)
FIGURE 20: CANADA SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)